Lonza announced the decision to set up its first Asian cell-therapy manufacturing plant in Singapore. This facility will initially manufacture products for clinical trials, and will build up Singapore's capabilities as one of Asia's leading sites for cell-therapy.
In addition, GlaxoSmithKline (GSK) recently embarked on a US$67 million upgrading project to improve the capability and flexibility of its Singapore manufacturing plant, which is one of GSK's key global sites that manufacture new pharmaceutical active ingredients. Coupled with its new R&D pilot plant opened in 2008, this upgrading project will support the seamless development and implementation of new processes from the R&D bench to full-scale manufacturing.
Marking a new milestone in its successful 31-year partnership with Singapore, Baxter Biosciences recently held a ground-breaking ceremony for a biopharmaceutical manufacturing plant for biologics and recombinant therapy. This facility is Singapore's sixth biologics manufacturing plant and will produce ADVATE, which is one of the world's most chosen recombinant FVIII therapies for hemophilia.
In response to the expanding base of biologics manufacturers in Singapore, which include Baxter, Genentech, GSK, Lonza and Novartis, Millipore opened a US$ 2 million regional biopharmaceutical manufacturing training facility.
In the field of micro-array, Singapore is emerging as a global leader with
|SOURCE Singapore Economic Development Board (EDB)|
Copyright©2009 PR Newswire.
All rights reserved